743 related articles for article (PubMed ID: 17577247)
1. Fecal M2-pyruvate kinase (M2-PK): a novel marker of intestinal inflammation.
Chung-Faye G; Hayee B; Maestranzi S; Donaldson N; Forgacs I; Sherwood R
Inflamm Bowel Dis; 2007 Nov; 13(11):1374-8. PubMed ID: 17577247
[TBL] [Abstract][Full Text] [Related]
2. Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease.
D'Haens G; Ferrante M; Vermeire S; Baert F; Noman M; Moortgat L; Geens P; Iwens D; Aerden I; Van Assche G; Van Olmen G; Rutgeerts P
Inflamm Bowel Dis; 2012 Dec; 18(12):2218-24. PubMed ID: 22344983
[TBL] [Abstract][Full Text] [Related]
3. Fecal pyruvate kinase is not suitable for discrimination between inflammatory bowel disease exacerbation and acute gastroenteritis.
Czub E; Nowak JK; Moczko J; Mankowski P; Lisowska A; Banaszkiewicz A; Banasiewicz T; Walkowiak J
Dev Period Med; 2015; 19(2):167-73. PubMed ID: 26384117
[TBL] [Abstract][Full Text] [Related]
4. Fecal dimeric M2-pyruvate kinase (tumor M2-PK) in the differential diagnosis of functional and organic bowel disorders.
Jeffery J; Lewis SJ; Ayling RM
Inflamm Bowel Dis; 2009 Nov; 15(11):1630-4. PubMed ID: 19462434
[TBL] [Abstract][Full Text] [Related]
5. Comparison of fecal pyruvate kinase isoform M2 and calprotectin in assessment of pediatric inflammatory bowel disease severity and activity.
Czub E; Nowak JK; Szaflarska-Poplawska A; Grzybowska-Chlebowczyk U; Landowski P; Moczko J; Adamczak D; Mankowski P; Banasiewicz T; Plawski A; Walkowiak J
Acta Biochim Pol; 2014; 61(1):99-102. PubMed ID: 24649481
[TBL] [Abstract][Full Text] [Related]
6. Validation of a point-of-care desk top device to quantitate fecal calprotectin and distinguish inflammatory bowel disease from irritable bowel syndrome.
Sydora MJ; Sydora BC; Fedorak RN
J Crohns Colitis; 2012 Mar; 6(2):207-14. PubMed ID: 22325175
[TBL] [Abstract][Full Text] [Related]
7. Faecal calprotectin as a novel biomarker for differentiating between inflammatory bowel disease and irritable bowel syndrome.
Chang MH; Chou JW; Chen SM; Tsai MC; Sun YS; Lin CC; Lin CP
Mol Med Rep; 2014 Jul; 10(1):522-6. PubMed ID: 24788223
[TBL] [Abstract][Full Text] [Related]
8. Faecal S100A12 as a non-invasive marker distinguishing inflammatory bowel disease from irritable bowel syndrome.
Kaiser T; Langhorst J; Wittkowski H; Becker K; Friedrich AW; Rueffer A; Dobos GJ; Roth J; Foell D
Gut; 2007 Dec; 56(12):1706-13. PubMed ID: 17675327
[TBL] [Abstract][Full Text] [Related]
9. Comparison of three commercial fecal calprotectin ELISA test kits used in patients with Inflammatory Bowel Disease.
Mirsepasi-Lauridsen HC; Bachmann Holmetoft U; Ingdam Halkjær S; Angeliki Krogfelt K; Munk Petersen A
Scand J Gastroenterol; 2016; 51(2):211-7. PubMed ID: 26359672
[TBL] [Abstract][Full Text] [Related]
10. Noninvasive markers in the assessment of intestinal inflammation in inflammatory bowel diseases: performance of fecal lactoferrin, calprotectin, and PMN-elastase, CRP, and clinical indices.
Langhorst J; Elsenbruch S; Koelzer J; Rueffer A; Michalsen A; Dobos GJ
Am J Gastroenterol; 2008 Jan; 103(1):162-9. PubMed ID: 17916108
[TBL] [Abstract][Full Text] [Related]
11. Elevated fecal M2-pyruvate kinase in children with cystic fibrosis: a clue to the increased risk of intestinal malignancy in adulthood?
Pang T; Leach ST; Katz T; Jaffe A; Day AS; Ooi CY
J Gastroenterol Hepatol; 2015 May; 30(5):866-71. PubMed ID: 25376228
[TBL] [Abstract][Full Text] [Related]
12. Clinical Performance of a Novel LIAISON Fecal Calprotectin Assay for Differentiation of Inflammatory Bowel Disease From Irritable Bowel Syndrome.
Campbell JP; Zierold C; Rode AM; Blocki FA; Vaughn BP
J Clin Gastroenterol; 2021 Mar; 55(3):239-243. PubMed ID: 32324678
[TBL] [Abstract][Full Text] [Related]
13. The prevalence of irritable bowel syndrome-type symptoms in inflammatory bowel disease patients in remission.
Hoekman DR; Zeevenhooven J; D'Haens GR; Benninga MA
Eur J Gastroenterol Hepatol; 2017 Sep; 29(9):1086-1090. PubMed ID: 28639969
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of noninvasive evaluations in monitoring inflammatory bowel disease activity: A prospective study in China.
Chen JM; Liu T; Gao S; Tong XD; Deng FH; Nie B
World J Gastroenterol; 2017 Dec; 23(46):8235-8247. PubMed ID: 29290660
[TBL] [Abstract][Full Text] [Related]
15. Fecal pyruvate kinase: a potential new marker for intestinal inflammation in children with inflammatory bowel disease.
Czub E; Herzig KH; Szaflarska-Popawska A; Kiehne K; Socha P; Woś H; Kamińska B; Błaszczyński M; Cichy W; Bała G; Brodzicki J; Grzybowska-Chlebowczyk U; Walkowiak J
Scand J Gastroenterol; 2007 Oct; 42(10):1147-50. PubMed ID: 17852864
[TBL] [Abstract][Full Text] [Related]
16. Neopterin is a novel reliable fecal marker as accurate as calprotectin for predicting endoscopic disease activity in patients with inflammatory bowel diseases.
Nancey S; Boschetti G; Moussata D; Cotte E; Peyras J; Cuerq C; Haybrard J; Charlois AL; Mialon A; Chauvenet M; Stroeymeyt K; Kaiserlian D; Drai J; Flourié B
Inflamm Bowel Dis; 2013 Apr; 19(5):1043-52. PubMed ID: 23511035
[TBL] [Abstract][Full Text] [Related]
17. Fecal calprotectin is an effective diagnostic tool that differentiates inflammatory from functional intestinal disorders.
Caviglia GP; Pantaleoni S; Touscoz GA; Adriani A; Rosso C; Smedile A; Pellicano R; Astegiano M; Bresso F
Scand J Gastroenterol; 2014 Dec; 49(12):1419-24. PubMed ID: 25369978
[TBL] [Abstract][Full Text] [Related]
18. From bench to bedside: Fecal calprotectin in inflammatory bowel diseases clinical setting.
Mumolo MG; Bertani L; Ceccarelli L; Laino G; Di Fluri G; Albano E; Tapete G; Costa F
World J Gastroenterol; 2018 Sep; 24(33):3681-3694. PubMed ID: 30197475
[TBL] [Abstract][Full Text] [Related]
19. Comparison of two immunoassays for measurement of faecal calprotectin in detection of inflammatory bowel disease: (pre)-analytical and diagnostic performance characteristics.
Oyaert M; Trouvé C; Baert F; De Smet D; Langlois M; Vanpoucke H
Clin Chem Lab Med; 2014 Mar; 52(3):391-7. PubMed ID: 24114912
[TBL] [Abstract][Full Text] [Related]
20. The prevalence of irritable bowel syndrome-type symptoms in paediatric inflammatory bowel disease, and the relationship with biochemical markers of disease activity.
Diederen K; Hoekman DR; Hummel TZ; de Meij TG; Koot BG; Tabbers MM; Vlieger AM; Kindermann A; Benninga MA
Aliment Pharmacol Ther; 2016 Jul; 44(2):181-8. PubMed ID: 27110920
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
